Procyon Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Procyon Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,831	Closed	-$207K	–	524
2023 Q3	$207K	Sell	2,831 -500	-15%	-$39.9K	0.02%	453
2023 Q2	$277K	Sell	3,331 -114	-3%	-$9.53K	0.03%	368
2023 Q1	$263K	Buy	3,445 +519	+18%	+$43.1K	0.04%	328
2022 Q4	$243K	Sell	2,926 -1,198	-29%	-$97K	0.04%	323
2022 Q3	$327K	Buy	+4,124	New	+$348K	0.08%	230
2021 Q4	–	Sell	-1,667	Closed	-$210K	–	352
2021 Q3	$210K	Buy	1,667 +1	+0.1%	+$129	0.05%	303
2021 Q2	$226K	Buy	1,666 +2	+0.1%	+$263	0.06%	268
2021 Q1	$226K	Sell	1,664 -135	-8%	-$20.2K	0.1%	223
2020 Q4	$253K	Buy	+1,799	New	+$230K	0.12%	194
2020 Q3	–	Sell	-791	Closed	-$89K	–	1078
2020 Q2	$89K	Sell	791 -94	-11%	-$9.26K	0.05%	306
2020 Q1	$69K	Buy	885 +110	+14%	+$9.74K	0.05%	288
2019 Q4	$74K	Buy	+775	New	+$67K	0.05%	297

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

CHP

Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return

MCM

Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Procyon Advisors's XBI Position: Q4 2023 in Review

Procyon Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 2,831 shares — an estimated $207K sold.

Procyon Advisors first reported a position in XBI in Q4 2019 and held it in 12 quarters. The position peaked at $327K in Q3 2022. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

Procyon Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
Procyon Advisors sold 2,831 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $207K.
Procyon Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and held it in 12 quarters.
Procyon Advisors's State Street SPDR S&P Biotech ETF position peaked at $327K in Q3 2022.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Procyon Advisors's 13F filing for Q4 2023, filed 18 Jan 2024.